ARS Pharmaceuticals Business Summary

ARS Pharmaceuticals, Inc. (SPRY) operates as a commercial-stage biopharmaceutical company primarily generating revenue through the direct sale of neffy®, the first and only FDA-approved needle-free nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s business model is centered on the commercialization of its proprietary intranasal epinephrine delivery technology, supplemented by strategic international licensing agreements with partners such as ALK-Abelló (Europe, Canada), Alfresa Pharma (Japan), and Pediatrix Therapeutics (China), which provide upfront payments, milestones, and royalties. ARS is currently expanding its clinical segment into chronic spontaneous urticaria (CSU) with its ARS-2 candidate, aiming to leverage its established delivery platform for broader dermatological and allergic indications. In the competitive landscape, ARS contends with traditional injectable manufacturers like Viatris (EpiPen) and Amneal Pharmaceuticals, as well as emerging needle-free rivals like Aquestive Therapeutics (Anaphylm). ARS distinguishes itself as a market disruptor, capturing share from legacy auto-injectors by addressing needle phobia and portability barriers. The company was co-founded by a veteran leadership team including Richard Lowenthal (President & CEO), Sarina Tanimoto, M.D. (Chief Medical Officer), and Robert Bell, Ph.D. (Chief Scientific Officer), all of whom bring extensive pedigrees in drug development and regulatory strategy from firms like Cadence Pharmaceuticals and Baxter. The executive suite is further bolstered by Kathleen Scott (CFO), Brian Dorsey (COO), and Eric Karas (Chief Commercial Officer), who oversees the global rollout of neffy. ARS is supported by a high-profile Board of Directors featuring Chairman Pratik Shah, Ph.D. and Brenton Saunders (former CEO of Allergan), alongside institutional representation from Peter Kolchinsky of RA Capital Management. Notable institutional backers include Orbimed Advisors, Deerfield Management, and Rubric Capital Management, reflecting strong capital market confidence in the company’s transition from a R&D-focused entity to a high-growth commercial powerhouse.